Want to see JP:4592 full AI Analyst Report?
4592 Stock Chart & Stats
¥957.00
¥9.00(0.94%)
At close: 4:00 PM EDT
¥957.00
¥9.00(0.94%)
Day’s Range― - ―
52-Week Range¥874.00 - ¥3,990.00
Previous CloseN/A
Volume557.50K
Average Volume (3M)2.08M
Market Cap
¥71.74B
Enterprise Value¥133.51K
Total Cash (Recent Filing)¥14.00B
Total Debt (Recent Filing)¥1.18B
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Sep 10, 2026EPS Estimate
-4.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-41.94
Shares Outstanding78,058,880
10 Day Avg. Volume2,869,570
30 Day Avg. Volume2,080,090
Financial Highlights & Ratios
PEG Ratio-1.38
Price to Book (P/B)9.94
Price to Sales (P/S)0.00
P/FCF Ratio-35.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,475.00Price Target Upside54.13% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-57.95
Revenue Forecast (FY)¥373.28M
Bulls Say, Bears Say
Bulls Say
Proprietary Allogeneic Cell Therapy PlatformSanBio’s proprietary allogeneic cell therapy platform (SB623) represents a durable competitive asset in regenerative CNS medicine. Platform IP and clinical program focus create high technical barriers to entry, support licensing/collaboration revenue paths, and sustain long-term strategic optionality.
Improved Equity PositionA materially larger equity base and expanded assets improve solvency metrics and underwriting capacity for ongoing R&D and regulatory milestones. This stronger capital base lengthens runway and reduces immediate liquidity stress, supporting sustained program development over months.
Generally Manageable LeverageDebt-to-equity in the low‑to‑mid‑20% range across recent years indicates financing structure that has been conservative outside of one spike. Manageable leverage gives financial flexibility for continued clinical investment and reduces immediate refinancing strain compared with highly levered peers.
Bears Say
No Commercial RevenueSanBio remains pre‑commercial with zero recurring product revenue, so the business model is unproven at scale. Long-term value depends on clinical/regulatory success and commercialization execution, making future cash generation binary and extending reliance on external funding until launch.
Sustained Negative Operating Cash FlowPersistent multi‑year cash burn demonstrates the company consumes substantial cash to fund trials and development. Continued negative OCF/Fcf increases dilution and refinancing risk, constrains strategic optionality, and makes long‑term program funding contingent on successful capital raises or partner deals.
Large And Persistent Net LossesConsistent, deep net losses reflect absence of scalable commercialization and negative returns on invested capital. Such losses suppress profitability metrics, limit retained earnings, and create ongoing pressure to raise funds, which can dilute shareholders and hinder long‑term capital allocation flexibility.
SanBio Co News
4592 FAQ
What was SanBio Co Ltd’s price range in the past 12 months?
SanBio Co Ltd lowest stock price was ¥874.00 and its highest was ¥3990.00 in the past 12 months.
What is SanBio Co Ltd’s market cap?
SanBio Co Ltd’s market cap is ¥71.74B.
When is SanBio Co Ltd’s upcoming earnings report date?
SanBio Co Ltd’s upcoming earnings report date is Sep 10, 2026 which is in 38 days.
How were SanBio Co Ltd’s earnings last quarter?
SanBio Co Ltd released its earnings results on Jun 15, 2026. The company reported -¥10.71 earnings per share for the quarter, missing the consensus estimate of -¥6.194 by -¥4.516.
Is SanBio Co Ltd overvalued?
According to Wall Street analysts SanBio Co Ltd’s price is currently Undervalued.
Does SanBio Co Ltd pay dividends?
SanBio Co Ltd does not currently pay dividends.
What is SanBio Co Ltd’s EPS estimate?
SanBio Co Ltd’s EPS estimate is -4.8.
How many shares outstanding does SanBio Co Ltd have?
SanBio Co Ltd has 78,058,880 shares outstanding.
What happened to SanBio Co Ltd’s price movement after its last earnings report?
SanBio Co Ltd reported an EPS of -¥10.71 in its last earnings report, missing expectations of -¥6.194. Following the earnings report the stock price went up 0.749%.
Which hedge fund is a major shareholder of SanBio Co Ltd?
Currently, no hedge funds are holding shares in JP:4592
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SanBio Co Ltd
SanBio Company Limited is dedicated to the creation, production, and sale of regenerative cell therapies, primarily concentrated on disorders of the central nervous system. A central component of their portfolio is SB623, a treatment that has completed Phase 2 clinical trials in both the United States and Japan for traumatic brain injury. Beyond this, their comprehensive research pipeline explores the broader potential of SB623 for conditions such as ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, and Alzheimer's disease. The company's development efforts also encompass other innovative treatments: SB618 for peripheral nerve damage, SB308 for muscular dystrophy, MSC1 for cancer, and MSC2 for inflammatory diseases and optic neuritis. Founded in 2001, SanBio maintains its corporate headquarters in Tokyo, Japan.
4592 Company Deck
4592 Earnings Call
Q4 2026
0:00 / 0:00
4592 Stock 12 Month Forecast
Average Price Target
¥1,475.00
▲(54.13% Upside)
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―